Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00605319
Other study ID # 0506007934
Secondary ID 2005-0202
Status Completed
Phase Phase 4
First received January 18, 2008
Last updated March 12, 2018
Start date January 2010
Est. completion date January 2013

Study information

Verified date March 2018
Source Weill Medical College of Cornell University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The subjects who have symptoms of overactive bladder (many trips to the bathroom, and urgency with or without the inability to hold your urine until you get to the toilet) are invited to participate in this research study.


Description:

Overactive bladder is a common sequelae of long-term bladder outlet obstruction in men. Unfortunately, it does not often resolve after treatment of the obstruction (transurethral resection of the prostate). These patients are usually started empirically on alpha-blockers or occasionally anticholinergic agents, former used to treat enlarged prostate medically, and latter, to treat overactive bladder. We hypothesize that these patients would be significantly improved with a long-acting anticholinergic agent such as long acting Fesoterodine or Toviaz.

Earlier studies have shown that anticholinergic drugs seem to have a beneficial effect on symptoms of patients with bladder outlet obstruction and overactive bladder. In addition, anticholinergic drug Toviaz is not associated with increased incidence of complication like acute urinary retention, a state where patient is unable to empty the bladder as an adverse effect of the drug.

A large proportion of our patients that are undergoing treatment for bladder outlet obstruction also have overactive bladder. We propose an open label trial to evaluate the efficacy of Toviaz (fesoterodine) 4mg to 8 mg in patients that have continued symptoms of overactive bladder one month following transurethral resection of the prostate. Toviaz is an antimuscarinic and anticholinergic agent, and is a newer formulation of Detrol. Patients with overactive bladder on urodynamic test preoperatively will be considered. If these patients continue to have symptoms at the one-month post-operative visit, they will be enrolled into the study. We expect a total of 25 patients to be enrolled within 4 months. All patients will receive Toviaz 4mg to 8 mg. The patients will be followed at 3 months post-op, 4 months post-op, and 7 months post-op. At each post-op visit, the patients will fill out an AUA symptom score questionnaire, have noninvasive uroflowmetry performed, and have a post-void residual measured by bladder scan. Using standard statistical analysis, we will see if there is a difference in symptoms, post-void residual, or maximum flow rate between baseline and 7 months post-op. We will continue the study to evaluate long-term efficacy, dropout rate, and complications. An FDA approved flexible dosing regimen will be allowed for the duration of the study.


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date January 2013
Est. primary completion date January 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 40 Years to 99 Years
Eligibility Patients will be selected by the investigator and sub-investigator's patient population, and physician referrals. All patients will meet the inclusion/ exclusion criteria.

Inclusion Criteria

1. Male =40 years of age

2. Clinical signs and symptoms of frequency and urgency, enlarged prostate and urodynamic study consistent with overactive bladder.

3. IPSS >12, with IPSS QoL > 3 at screening visit.

4. Ability and willingness to correctly complete the micturition diary and all the trial related questionnaires comply with scheduled visits and comply with trial procedures.

5. Capability of understanding and having signed the informed consent form after full discussion of the research, nature of the treatment, and its risks and benefits.

6. Procedure to treat BOO by TURP or PVP greater than or equal to 1 month ago.

Exclusion Criteria

1. A known history of interstitial cystitis, uninvestigated hematuria, or bladder outlet obstruction due to: mullerian duct cysts, urethral obstruction due to stricture/valves/sclerosis of urethral tumor, radiation cystitis, genitourinary tuberculosis, bladder calculi, or detrusor-sphincter dyssynergia.

2. Evidence of Urinary Tract Infection according to local standard of care.

3. Expectation of initiating treatment during the duration of this study with - any drug treatment for OAB, any drugs with significant anticholinergic, antispasmodic, parasympathetic, or cholinergic agonistic effects.

4. Use of any electrostimulation within the 30 days before randomization, or the expectation to initiate such therapy during the study.

5. Any condition which, in the opinion of the investigator, makes the patient unstable, or with contraindications for inclusion, e.g., uncontrolled narrow-angled glaucoma, urinary retention, preplanned prostate surgery, or gastric retention.

6. Significant hepatic or renal disease, defined as twice the upper limit of the reference ranges regarding serum concentrations of AST, ALT, ALP, urea nitrogen, or creatinine.

7. Use of any other investigational drug in the 2 months preceding visit 1.

8. History of postural hypotension or syncope in the judgement of the investigator based on local standards of care.

9. Alcohol and/or any other drug abuse in the opinion of the investigator.

10. Medications such as erythromycin, Biaxin (Clarithromycin), Sporanox (itraconazole), Nizoral (ketoconazole), Neoral and Sandimmune (cyclosporine), Velban (vinblastine) and miconazole.

11. Non-medication treatments such as bio-feedback or other bladder training exercises.

Study Design


Intervention

Drug:
Toviaz (Fesoterodine)
4mg to 8mg by mouth once daily

Locations

Country Name City State
United States New York Hospital, Cornell University New York New York

Sponsors (2)

Lead Sponsor Collaborator
Weill Medical College of Cornell University Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary IPSS Obstructive International Prostate Symptom Score (IPSS) -is a 7 point scale used to screen, track and manage symptoms associated with BPH for obstructive, irritative, nocturia. The symptoms questions include feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. Scores range from 1 to 5 for a total of maximum 35 points (0-7 Mildly symptomatic, 8-19 Moderately symptomatic, 20-35 Severely symptomatic). This measure was taken for patients with obstructive symptoms which includes hesitancy or difficulty initiating the stream, straining to void, a reduced flow, an intermittent stream or a sensation of incomplete emptying. screening (Month 0), 2-months, 3-months, 7-months
Primary IPSS Irritative International Prostate Symptom Score (IPSS) -is a 7 point scale used to screen, track and manage symptoms associated with BPH for obstructive, irritative, nocturia. The symptoms questions include feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. Scores range from 1 to 5 for a total of maximum 35 points (0-7 Mildly symptomatic, 8-19 Moderately symptomatic, 20-35 Severely symptomatic). This measure was taken for patients with irritative symptoms which includes frequency, urgency, nocturia and urge incontinence screening (Month 0), 2-months, 3-months, 7-months
Primary IPSS Nocturia International Prostate Symptom Score (IPSS) -is a 7 point scale used to screen, track and manage symptoms associated with BPH for obstructive, irritative, nocturia. The symptoms questions include feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. Scores range from 1 to 5 for a total of maximum 35 points (0-7 Mildly symptomatic, 8-19 Moderately symptomatic, 20-35 Severely symptomatic). This measure was taken for patients with nocturia meaning individuals who wake up during sleeping hours to urinate. screening (Month 0), 2-months, 3-months, 7-months
Primary International Prostate Symptom Score (IPSS) Quality of Life (QoL) IPSS Quality of Life (QoL) is one question used to assess how the patient's symptoms affect their quality of life. A score ranges from 1 to 6, with 6 being the worse outcome. screening (Month 0), 2-months, 3-months, 7-months
Primary Maximum Flow Rate (Qmax) Urodynamics was used to meause maximum flow rate (Qmax) which is the maximum recorded flow rate of urinary screening (Month 0), 2-months, 3-months, 7-months
Primary Average Flow Rate (Qavg) Average (mean) flow rate (Qavg) is the the volume of urine voided divided by the continuous flow time screening (Month 0), 2-months, 3-months, 7-months
Primary Postvoid Residual Volume (PVR) Postvoid residual volume (PVR) is the volume of fluid remaining in the bladder immediately after the completion of micturition. screening (Month 0), 2-months, 3-months, 7-months
See also
  Status Clinical Trial Phase
Recruiting NCT03457805 - Prostatic Artery Embolization in Advanced Prostate Cancer N/A
Completed NCT00507455 - Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction Phase 2
Recruiting NCT04626167 - Concomitant Renal and Urinary Bladder Allograft Transplantation Early Phase 1
Not yet recruiting NCT06422312 - A Study Comparing a Disposable Flexible Cystoscope With Reusable Scopes in Adult Patients. N/A
Suspended NCT01779349 - Bladder Outlet Obstruction Observation Using Dynamic Urine Vibration "Holter" N/A
Not yet recruiting NCT01388348 - Diagnosis of Bladder Outlet Obstruction Using Dynamic Urine Vibration "Holter" in Comparison to Pressure Flow Study N/A
Completed NCT00710749 - The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects N/A
Recruiting NCT03486639 - Urodynamics and Clinical Factors That Are Associated With Bladder Over-sensitivity
Enrolling by invitation NCT02869061 - Effectiveness and Safety of Adipose-derived Regenerative Cells for Reduction of Risk of Bladder Neck Contracture Phase 1/Phase 2
Active, not recruiting NCT05631080 - Transurethral Prostate Enucleation in Surveillance Protocol for Low Risk Prostate Cancer Phase 4
Completed NCT02031653 - Comparison Between Invasive Pressure Flow Study and Non-invasive Penile Cuff Test
Recruiting NCT03503721 - Bipolar Transurethral Enucleation (BipolEP) vs Bipolar Transurethral Resection of the Prostate N/A
Not yet recruiting NCT05910983 - Prostate Enucleation With Intravesical Botox Injections in Treating BPH and Bladder Overactivity N/A
Recruiting NCT03281798 - Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction N/A
Completed NCT05470751 - GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology
Completed NCT04981080 - DU and BOO in Women With and Without Symptoms of VD
Completed NCT00410514 - A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO) Phase 2
Recruiting NCT06152666 - Day-case Endourology; Enablers, Barriers, Unexpected Outcomes
Not yet recruiting NCT04514718 - Low Energy HoLEP on IPSS N/A
Completed NCT01661621 - Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1 Phase 4